We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
febit to Receive Funding from a Federal Grant Awarded in the German Excellence Cluster Contest
News

febit to Receive Funding from a Federal Grant Awarded in the German Excellence Cluster Contest

febit to Receive Funding from a Federal Grant Awarded in the German Excellence Cluster Contest
News

febit to Receive Funding from a Federal Grant Awarded in the German Excellence Cluster Contest

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "febit to Receive Funding from a Federal Grant Awarded in the German Excellence Cluster Contest"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

As early as mid-February, febit will start setting up the Biomarker Discovery Center Heidelberg, one of the projects recently awarded funding from the Excellence Cluster Initiative of the German Federal Ministry of Education and Research (BMBF).

Together, the projects of the companies involved in the Biotech Excellence Cluster Rhine-Neckar were granted a total of 40 million Euros for the development of innovative drugs, diagnostics and technologies in cellular and molecular biology.

febit convinced the jury with two projects: in mid-February febit will start combining microarray technology and high-throughput sequencing (Next Generation Sequencing) to create powerful and cost-effective procedures for the development and validation of novel biomarkers.

The second project aims at the determination of novel tumor markers. Collaborating with the German Cancer Research Center (DKFZ), febit will conduct studies directed at the identification of markers for various cancer types and develop these into standardized diagnostic assays in the near future.

“We are pleased that the grant gives us the opportunity to initiate these scientifically advanced projects. febit´s highly versatile and equally automatable technology is ideally suited for the use in diagnostics requiring individual investigations with standardized procedures,“ explains febit CSO Peer Stahler.

This particular technology will be able to identify candidate markers which are then statistically analyzed by a package of software algorithms. A novel DNA enrichment technology will capture samples for high-throughput sequencing machines, thus allowing rapid and efficient characterization of genes involved in tumor formation.
Advertisement